Erik Ingelsson
Chief Scientific Officer @Wave Life Sciences
Signup · Get unlimited contacts
WORK HISTORY
Chief Scientific Officer @Wave Life Sciences
Boston, MA, US
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM™, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a strong preclinical pipeline, including an INHBE program with a potentially best-in-class profile for obesity.
EDUCATION
Uppsala University
Doctor of Philosophy (PhD), Epidemiology
Uppsala University
MD, Medicine
SKILLS
ABOUT ERIK INGELSSON
A seasoned physician-scientist with a 20-year tenure in academia – last as Professor of Medicine at Stanford University – I seamlessly transitioned to industry in 2020. After 4 years in different roles at GSK – last as Senior Vice President, Target Discovery – I joined Wave Life Sciences as Chief Scientific Officer in May 2024. Being known for fostering high-performance cultures that prioritize open communication and creativity, my ultimate goal is to leverage my medical expertise and drug development experience to discover groundbreaking medicines addressing unmet patient needs.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.